2. Hansen J. Night shift work and risk of breast cancer. Curr Environ Health Rep. 2017; 4(3):325–339.
3. Wegrzyn LR, Tamimi RM, Rosner BA, Brown SB, Stevens RG, Eliassen AH, et al. Rotating night-shift work and the risk of breast cancer in the nurses' health studies. Am J Epidemiol. 2017; 186(5):532–540.
4. Lee HE, Lee J, Jang TW, Kim IA, Park J, Song J. The relationship between night work and breast cancer. Ann Occup Environ Med. 2018; 30:11.
5. Rao D, Yu H, Bai Y, Zheng X, Xie L. Does night-shift work increase the risk of prostate cancer? a systematic review and meta-analysis. Onco Targets Ther. 2015; 8:2817–2826.
6. Du HB, Bin KY, Liu WH, Yang FS. Shift work, night work, and the risk of prostate cancer: a meta-analysis based on 9 cohort studies. Medicine (Baltimore). 2017; 96(46):e8537.
7. Kubo T, Oyama I, Nakamura T, Kunimoto M, Kadowaki K, Otomo H, et al. Industry-based retrospective cohort study of the risk of prostate cancer among rotating-shift workers. Int J Urol. 2011; 18(3):206–211.
8. Wendeu-Foyet MG, Bayon V, Cénée S, Trétarre B, Rébillard X, Cancel-Tassin G, et al. Night work and prostate cancer risk: results from the EPICAP Study. Occup Environ Med. 2018; 75(8):573–581.
9. Flynn-Evans EE, Mucci L, Stevens RG, Lockley SW. Shiftwork and prostate-specific antigen in the National Health and Nutrition Examination Survey. J Natl Cancer Inst. 2013; 105(17):1292–1297.
10. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324(17):1156–1161.
11. Crawford JO, Cherrie JW, Davis A, Dixon K, Alexander C, Cowie H, et al. A review of the impact of shift work on occupational cancer: part 2–mechanistic and health and safety evidence. Policy Pract Health Saf. 2018; 16(1):109–144.
12. Conlon M, Lightfoot N, Kreiger N. Rotating shift work and risk of prostate cancer. Epidemiology. 2007; 18(1):182–183.
13. Parent MÉ, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. Night work and the risk of cancer among men. Am J Epidemiol. 2012; 176(9):751–759.
14. Behrens T, Rabstein S, Wichert K, Erbel R, Eisele L, Arendt M, et al. Shift work and the incidence of prostate cancer: a 10-year follow-up of a German population-based cohort study. Scand J Work Environ Health. 2017; 43(6):560–568.
15. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006; 164(6):549–555.
16. Rybnikova NA, Haim A, Portnov BA. Is prostate cancer incidence worldwide linked to artificial light at night exposures? Review of earlier findings and analysis of current trends. Arch Environ Occup Health. 2017; 72(2):111–122.
17. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004; 229(4):277–284.
18. Fritschi L, Glass DC, Heyworth JS, Aronson K, Girschik J, Boyle T, et al. Hypotheses for mechanisms linking shiftwork and cancer. Med Hypotheses. 2011; 77(3):430–436.
19. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007; 8(12):1065–1066.
20. Irwin M, McClintick J, Costlow C, Fortner M, White J, Gillin JC. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 1996; 10(5):643–653.
21. Dimitrov S, Lange T, Tieken S, Fehm HL, Born J. Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans. Brain Behav Immun. 2004; 18(4):341–348.
22. Sallinen M, Kecklund G. Shift work, sleep, and sleepiness - differences between shift schedules and systems. Scand J Work Environ Health. 2010; 36(2):121–133.
23. Dal Maso L, Zucchetto A, Tavani A, Montella M, Ramazzotti V, Polesel J, et al. Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer. 2006; 118(10):2632–2635.
24. Friedenreich CM, Thune I. A review of physical activity and prostate cancer risk. Cancer Causes Control. 2001; 12(5):461–475.
25. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010; 14(8):iiiix–xi. 1–193.
26. Pater LE, Hart KW, Blonigen BJ, Lindsell CJ, Barrett WL. Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population. Am J Clin Oncol. 2012; 35(5):490–492.
27. Bonn SE, Sjölander A, Tillander A, Wiklund F, Grönberg H, Bälter K. Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. Int J Cancer. 2016; 139(1):50–57.
28. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005; 103(5):1092–1095.
29. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology. 2005; 65(4):708–712.
30. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006; 175(2):500–504.
31. Loprinzi PD, Kohli M. Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003–2006. Mayo Clin Proc. 2013; 88(1):11–21.
32. Kim SH, Jang KH, Park WJ, Kwon DH, Kang WY, Lim HM, et al. Serum prostate-specific antigen levels and type of work in tire manufacturing workers. Ann Occup Environ Med. 2014; 26(1):50.
33. Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, et al. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int. 2009; 103(9):1168–1172.
34. Wong LI, Labrecque MP, Ibuki N, Cox ME, Elliott JE, Beischlag TV. p,p′-Dichlorodiphenyltrichloroethane (p,p′-DDT) and p,p′-dichlorodiphenyldichloroethylene (p,p′-DDE) repress prostate specific antigen levels in human prostate cancer cell lines. Chem Biol Interact. 2015; 230:40–49.
35. Tarhan F, Demir K, Orcun A, Madenci OC. Effect of ejaculation on serum prostate-specific antigen concentration. Int Braz J Urol. 2016; 42(3):472–478.
36. Bayraktar Z, Inan EH, Bayraktar V. Effect of constipation on serum total prostate-specific antigen levels in men. Int J Urol. 2012; 19(1):54–59.
37. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542–1547.
38. Kantermann T, Juda M, Vetter C, Roenneberg T. Shift‐work research: Where do we stand, where should we go? Sleep Biol Rhythms. 2010; 8(2):95–105.
39. Papantoniou K, Castaño-Vinyals G, Espinosa A, Aragonés N, Pérez-Gómez B, Burgos J, et al. Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study. Int J Cancer. 2015; 137(5):1147–1157.